This article presents optimization of drug schedule for cycle-specific chemotherapy by multi-objective evolutionary algorithm NSGA-II. The possible response of tumor and normal cells under the influence of cycle-specific drugs is formulated as an optimal control problem. The objective is to minimize ...
In transgenic mice, overexpression of several of these cell cycle proteins induces or contributes to tumorigenesis, revealing their prominent oncogenic roles. Some of these cell cycle proteins are also required for tumorigenesis, and their ablation in mice impairs tumour formation induced by specific ...
N. Cell Cycle Phase-Specific Chemotherapy: Computation Methods for Guiding Treatment. Cell Cycle 2002, 1, 369.S. N. Gardner. Cell cycle phase-specific chemotherapy: Computation methods for guiding treatment. Cell cycle, 6(1):369-374, 2002....
Analysis of the toxicity of chemotherapeutic drugs is one of the main tasks of clinical pharmacology. Decreased viability of tumor cells may reflect two important physiological processes, namely the arrest of proliferation associated with disturbances in cellular metabolism or actual cell death. Elucidation...
cells which express high level of GSDME, while cells with low or no GSDME expression undergo apoptosis. However, in some tumor cell lines, the expression level of GSDME was lower than that in normal cell lines, leading to the accidental injury of normal tissues during chemotherapy [38,124]....
Additionally, we also applied DREEP to molecularly barcoded breast cancer cells and identified drugs that can selectively target specific cell populations. Conclusions DREEP provides an in silico framework to prioritize drugs from single-cell transcriptional profiles of tumours and thus helps in ...
Neoadjuvant chemotherapy (NAC) is a well-established treatment modality for locally advanced breast cancer (BC). However, it can also result in severe toxicities while controlling tumors. Therefore, reliable predictive biomarkers are urgently needed to o
Recent clinical trials have only provided support for the efficacy of sunitinib and lenvatinib, both multi-tyrosine kinase receptor inhibitors, in the context of chemotherapy-refractory TETs [7, 8]. The feasibility of utilizing pembrolizumab and nivolumab exclusively as non-first-line therapies for ...
Drugs Conferences Antivirals Conferences Generics Conferences Applied Microbiology Conferences Vaccines Conferences Biometrics Conferences Inhibitors Conferences Biosystems Engineering Conferences Receptors Conferences Brain Tumors Conferences Pharmacy Conferences Cell Biology Conferences Pharmacies Conferences...
Aberrant activity of cell cycle protein kinases, leading to uncontrolled cell proliferation, is a hallmark of human cancer. Here, Lapenna and Giordano review recent progress in the modulation of specific protein kinase activity for the treatment of vario